Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Chenze Li, MD candidate
- Phone Number: 86-27-83663280
- Email: lichenze@126.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital
-
Contact:
- Chenze Li, MD candidate
- Phone Number: 86-27-83663280
- Email: lichenze@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
· Patients diagnosed as cardiomyopathy according to the definition of American Heart Association
Exclusion Criteria:
- Uncontrolled hypertension significant valvular disease
- Mild ischemic heart disease
- Significant systemic infection
- Thyroid-induced cardiomyopathy
- Excessive alcohol consumption
- Precious cancer treatment including irradiation
- Refusal to participate in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiovascular death confirmed by death comfirmation or interview with the relatives
Time Frame: up to 24 months
|
Death from cardiovascular causes and any unknown death unless there was another certain cause
|
up to 24 months
|
|
Heart transplantation confirmed by medical record
Time Frame: up to 24 months
|
Heart transplantation within 24 months
|
up to 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All cause death confirmed by death comfirmation or interview with the relatives
Time Frame: up to 24 months
|
Any death at hospital or after discharge
|
up to 24 months
|
|
Heart failure recurring confirmed by medical record
Time Frame: up to 24 months
|
Recurrence of heart failure at hospital or after discharge
|
up to 24 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Readmission because of cardiovascular diseases confirmed by medical record
Time Frame: up to 24 months
|
Readmission because of cardiovascular diseases within 24 months
|
up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Dao Wen Wang, Doctor, Tongji Hospital,Wuhan, Hubei, China, 430030
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TJ-DM-GENE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy
-
NCT02989454Completed
-
NCT06794710Not yet recruitingHypertrophic Cardiomyopathy (HCM) | Restrictive Cardiomyopathy | Metabolic Cardiomyopathy | Dilated Cardiomyopathy (DCM)
-
NCT06748261Not yet recruitingCardiovascular Diseases | Myocarditis | Cardiomyopathies | Ischemic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Hypertrophic Cardiomyopathy (HCM) | Restrictive Cardiomyopathy | Amyloid Cardiomyopathy | Dilated Cardiomyopathy (DCM)
-
NCT00703443WithdrawnDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive Cardiomyopathy | Mitochondrial Cardiomyopathy | Noncompaction Cardiomyopathy
-
NCT02293603UnknownHeart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)
-
NCT04265040RecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction Cardiomyopathy
-
NCT05648825Active, not recruitingTransapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic CardiomyopathyNonobstructive Hypertrophic Cardiomyopathy
-
NCT07420907RecruitingHeart Failure | Hypertension | Aortic Stenosis | Dilated Cardiomyopathy | Cardiovascular Disease (CVD) | Aortic Stenosis Disease | Dilated Cardiomyopathy, Familial | Hypertension (HTN) | Dilated Cardiomyopathy (DCM) | Hypertrophic Cardiomyopathy Patients
-
NCT03572569UnknownDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Left Ventricular Noncompaction | Primary Cardiomyopathy
-
NCT04978987CompletedHeart Failure | Cardiomyopathy, Familial | Phospholamban R14del Cardiomyopathy